Silexion Doses First Patient in Phase 2/3 Trial for Locally Advanced…

Event summary

First patient dosed in Phase 2/3 trial of SIL204 for locally advanced pancreatic cancer (LAPC) on September 30, 2026.
Trial combines SIL204 with standard chemotherapy, using dual-route delivery (EUS-guided intratumoral and subcutaneous).
Initial safety run-in cohort of 18 patients, expanding to 166 patients globally.
Tel Aviv Sourasky Medical Center serves as the anchor clinical center in Israel.

The big picture

Silexion's Phase 2/3 trial of SIL204 represents a strategic push into the challenging LAPC space, where KRAS mutations are prevalent and treatment options are limited. The dual-route delivery approach aims to overcome the biological barriers of pancreatic tumors, a critical innovation in oncology. Success in this trial could position SIL204 as a potential first-line treatment, addressing a significant unmet need in pancreatic cancer therapy.

What we're watching

Trial Execution: The pace at which additional clinical sites in Israel and Germany are activated will determine the trial's global expansion and enrollment timelines.
Clinical Efficacy: Whether SIL204 demonstrates statistically significant improvements in response rates and survival outcomes compared to chemotherapy alone.
Regulatory Dynamics: How the Israeli Ministry of Health and BfArM approvals impact the trial's progression and potential future regulatory pathways.